Table 4.
Results of univariate analyses for the risk of advanced liver fibrosis † in chronic hepatitis B patients.
| Variable | n (%) | OR | 95% Cl | p-Value |
|---|---|---|---|---|
|
Age >50 years ≤50 years |
346 (53%) 306 (47%) |
2.98 | 2.15–4.12 | <0.001 |
|
Sex Female Male |
242 (37%) 410 (63%) |
0.39 | 0.28–0.55 | <0.001 |
|
Alcohol consumption YES NO |
332 (51%) 320 (49%) |
1.70 | 1.21–2.40 | 0.002 |
|
Previous treatment YES NO |
308 (47%) 344 (53%) |
3.19 | 2.23–4.57 | <0.001 |
|
Portal hypertension YES NO |
254 (39%) 398 (61%) |
7.32 | 4.98–10.76 | <0.001 |
|
AST >50 IU/L ≤50 IU/L |
118 (18%) 534 (82%) |
3.76 | 2.07–6.84 | <0.001 |
|
ALT >42 IU/L ≤42 IU/L |
98 (15%) 554 (85%) |
0.62 | 0.44–0.87 | 0.006 |
|
PLT >150 IU/L ≤150 IU/L |
502 (77%) 150 (23%) |
6.64 | 4.11–10.74 | <0.001 |
|
HBV DNA >6000 kIU/mL ≤6000 kIU/mL |
529 (81%) 123 (19%) |
1.76 | 1.13–2.73 | 0.011 |
|
AST/ALT >1 ≤1 |
254 (39%) 398 (61%) |
1.44 | 1.02–2.04 | 0.036 |
| XRCC1 rs25487 | ||||
| CC vs. TT | 294 (45) vs. 104 (16) | 1.26 | 0.82–1.94 | 0.29 |
| CC vs. CT, TT | 294 (45%) vs. 358 (55%) | 0.69 | 0.51–0.95 | 0.024 |
| TT vs. CT, CC | 104 (16%) vs. 548 (84%) | 0.78 | 0.49–1.22 | 0.27 |
| ERCC2 rs238406 | ||||
| GG vs. TT | 235 (36) vs. 154 (23.5) | 0.92 | 0.59–1.42 | 0.70 |
| GG vs. GT, TT | 235 (36) vs. 417 (64) | 1.04 | 0.76–1.42 | 0.79 |
| TT vs. GT, GG | 154 (23.5) vs. 498 (76.5) | 0.91 | 0.97–1.44 | 0.68 |
| ERCC2 rs13181 | ||||
| TT vs. GG | 303 (46.5) vs. 117 (17) | 2.85 | 0.66–12.39 | 0.16 |
| GG vs. GT, TT | 117 (18) vs. 535 (82) | 1.17 | 0.78–1.76 | 0.43 |
| TT vs. GT, GG | 303 (46.5) vs. 349 (53.5) | 0.90 | 0.66–1.23 | 0.53 |
| ERCC5 rs2018836 | ||||
| GG vs. AA | 333 (51) vs. 88 (13.5) | 0.73 | 0.47–1.14 | 0.17 |
| GG vs. GA, AA | 333 (51) vs. 319 (49) | 1.04 | 0.73–1.49 | 0.80 |
| AA vs. GA, GG | 88 (13.5) vs. 564 (86.5) | 0.64 | 0.42–0.96 | 0.031 |
| RAD 52 rs7963551 | ||||
| TT vs. GG | 492 (75.5) vs. 72 (11) | 1.67 | 1.04–2.68 | 0.032 |
| TT vs. TG, GG | 492 (75.5) vs. 160 (24.5) | 0.66 | 0.46–0.97 | 0.034 |
| GG vs. TG, TT | 72 (11) vs. 580 (89) | 1.54 | 0.94–2.54 | 0.08 |
| MRE 11 rs496797 | ||||
| TT vs. CC | 163 (25) vs. 209 (32) | 0.94 | 0.63–1.42 | 0.79 |
| TT vs. TC, CC | 163 (25) vs. 489 (75) | 0.88 | 0.62–1.26 | 0.49 |
| CC vs. TC, TT | 209 (32) vs. 443 (68) | 0.83 | 0.59–1.16 | 0.28 |
| MRE 11 rs535801 | ||||
| CC vs. TT | 316 (48.5) vs. 95 (14.5) | 0.86 | 0.56–1.30 | 0.47 |
| CC vs. CT, TT | 316 (48.5) vs. 336 (51.5) | 1.15 | 0.84–1.57 | 0.37 |
| TT vs. CT, CC | 95 (14.5) vs. 557 (85.5) | 0.95 | 0.62–1.46 | 0.83 |
| NBN rs2735383 | ||||
| CC vs. GG | 336 (51.5) vs. 101 (15.5) | 1.03 | 0.68–1.57 | 0.88 |
| CC vs. CG, GG | 336 (51.5) vs. 316 (48.5) | 0.88 | 0.64–1.21 | 0.45 |
| GG vs. CG, CC | 101 (15.5) vs. 551 (84.5) | 0.55 | 0.55–1.31 | 0.46 |
| XRCC4 rs1805377 | ||||
| GG vs. AA | 522 (80) vs. 13 (2) | 1.23 | 0.63–2.39 | 0.54 |
| GG vs. GA, AA | 522 (80) vs. 130 (20) | 0.84 | 0.57–1.24 | 0.39 |
| AA vs. GA, GG | 13 (2) vs. 639 (98) | 0.81 | 0.27–2.41 | 0.71 |
CI, confidence interval; MAF, minor allele frequency. p-values less than 0.05 are marked in bold. † S > 2.